Evolving antiepileptic drug treatment in juvenile myoclonic epilepsy

被引:71
|
作者
Prasad, A
Kuzniecky, RI
Knowlton, RC
Welty, TE
Martin, RC
Mendez, M
Faught, RE
机构
[1] Univ Alabama Birmingham, Sch Med, Epilepsy Ctr, Civitan Int Res Ctr 312,Epilepsy Div,Dept Neurol, Birmingham, AL 35294 USA
[2] Samford Univ, McWhorter Sch Pharm, Dept Pharm, Birmingham, AL USA
关键词
D O I
10.1001/archneur.60.8.1100
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: In the face of availability of newer anti-epileptic drugs (AEDs) such as lamotrigine and topiramate, there is need to reassess the role of older AEDs in the treatment of juvenile myoclonic epilepsy (JME). Objectives: To explore whether lamotrigine and topiramate monotherapy or polytherapy can be effective options in the treatment of JME, and to determine whether older AEDs, such as phenytoin and carbamazepine, have a role in the treatment of JME. Design: A retrospective cohort study. Setting: A large academic teaching hospital. Patients: Seventy-two consecutive JME patients treated with valproic acid, lamotrigine, topiramate, phenytoin, or carbamazepine between April 1, 1991, and March 3 1, 2001. Methods: We compared the efficacy of valproic acid, lamotrigine, and topiramate monotherapy or polytherapy in the control of different seizure types of JME, and compared their efficacy and tolerability with the efficacy and tolerability of phenytoin and carbamazepine. Results: Seizure outcome did not differ when patients receiving valproic acid monotherapy (n = 36) were compared with those receiving lamotrigine monotherapy (n = 14), and when patients receiving valproic acid polytherapy (n = 22) were compared with those receiving lamotrigine polytherapy (n = 21) or topiramate polytherapy (n = 15) (P >. 05 for all). The combined data of myoclonic seizure control by all 3 AEDs were poorer when compared with the combined data of generalized tonic-clonic seizure control by all 3 AEDs (P = .03), but not when compared with the combined data of absence seizure control by all 3 AEDs (P = .43). Valproic acid, lamotrigine, and topiramate, when compared with phenytoin or carbamazepine, demonstrated significantly better control of myoclonic seizures (P < .01 for all), but not of generalized tonic-clonic seizures (P >. 11 for all). Conclusions: Lamotrigine and topiramate are effective alternative options to valproic acid in the treatment of JME. Lamotrigine is an effective option as monotherapy and polytherapy. Topiramate is an effective option as polytherapy, but more data are needed to determine if it is an effective option as monotherapy. More effective therapy is needed to improve myoclonic seizure control. Older AEDs, such as phenytoin and carbamazepine, may not be indicated in JME patients.
引用
收藏
页码:1100 / 1105
页数:6
相关论文
共 50 条
  • [1] Evolving antiepileptic drug treatment in juvenile myoclonic epilepsy
    Grunewald, RA
    Salas-Puig, J
    Genton, P
    Panayiotopoulos, CP
    [J]. ARCHIVES OF NEUROLOGY, 2004, 61 (08) : 1328 - 1328
  • [2] Antiepileptic drug withdrawal in juvenile myoclonic epilepsy
    Syvertsen, Marte
    Flogstad, Ida
    Enger, Ulla
    Landmark, Cecilie Johannessen
    Koht, Jeanette
    [J]. ACTA NEUROLOGICA SCANDINAVICA, 2019, 139 (02): : 192 - 198
  • [3] Treatment and challenges with antiepileptic drugs in patients with juvenile myoclonic epilepsy
    Landmark, Cecilie Johannessen
    Flogstad, Ida
    Syvertsen, Marte
    Baftiu, Arton
    Enger, Ulla
    Koht, Jeanette
    Johannessen, Svein, I
    [J]. EPILEPSY & BEHAVIOR, 2019, 98 : 110 - 116
  • [4] Retrospective Analysis Of Antiepileptic Drug Effectiveness And Tolerability In Juvenile Myoclonic Epilepsy
    Silvennoinen, K.
    de Lange, N.
    Zagaglia, S.
    Balestrini, S.
    Androsova, G.
    Borghei, M.
    Wassenaar, M.
    Auce, P.
    Avbersek
    Becker, F.
    Berghuis, B.
    Campbell, E.
    Coppola, A.
    Francis, B.
    Wolking, S.
    Cavalleri, G. L.
    Craig, J.
    Delanty, N.
    Johnson, M. R.
    Koeleman, B. P. C.
    Kunz, W. S.
    Lerche, H.
    Marson, A. G.
    O'Brien, T. J.
    Sander, J. W.
    Sills, G. J.
    Striano, P.
    Zara, F.
    Krause, R.
    Depondt, C.
    Sisodiya, S. M.
    [J]. EPILEPSIA, 2018, 59 : S219 - S220
  • [5] Relapse after treatment withdrawal of antiepileptic drugs for Juvenile Absence Epilepsy and Juvenile Myoclonic Epilepsy
    Healy, Liam
    Moran, Maria
    Singhal, Sumeet
    O'Donoghue, Michael F.
    Alzoubidi, Rania
    Whitehouse, William P.
    [J]. SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2018, 59 : 116 - 122
  • [6] Antiepileptic Drug (AED) Treatment in Juvenile Myoclonic Epilepsy (JME): a Population-based Study
    Oh, Ahyuda
    Kim, Hyunmi
    [J]. NEUROLOGY, 2020, 94 (15)
  • [7] Juvenile myoclonic epilepsy: long-term prognosis and antiepileptic drug withdrawal
    Viloria Alebesque, A.
    Bellosta Diago, E.
    Santos Lasaosa, S.
    Mauri Llerda, J. A.
    [J]. ANALES DEL SISTEMA SANITARIO DE NAVARRA, 2020, 43 (01) : 43 - 49
  • [8] Comparative effectiveness of antiepileptic drugs in juvenile myoclonic epilepsy
    Silvennoinen, Katri
    de Lange, Nikola
    Zagaglia, Sara
    Balestrini, Simona
    Androsova, Ganna
    Wassenaar, Merel
    Auce, Pauls
    Avbersek, Andreja
    Becker, Felicitas
    Berghuis, Bianca
    Campbell, Ellen
    Coppola, Antonietta
    Francis, Ben
    Wolking, Stefan
    Cavalleri, Gianpiero L.
    Craig, John
    Delanty, Norman
    Johnson, Michael R.
    Koeleman, Bobby P. C.
    Kunz, Wolfram S.
    Lerche, Holger
    Marson, Anthony G.
    O'Brien, Terence J.
    Sander, Josemir W.
    Sills, Graeme J.
    Striano, Pasquale
    Zara, Federico
    van der Palen, Job
    Krause, Roland
    Depondt, Chantal
    Sisodiya, Sanjay M.
    [J]. EPILEPSIA OPEN, 2019, 4 (03) : 420 - 430
  • [9] Treatment of juvenile myoclonic epilepsy
    Auvin, Stephane
    [J]. CNS NEUROSCIENCE & THERAPEUTICS, 2008, 14 (03) : 227 - 233
  • [10] Treatment Options in Juvenile Myoclonic Epilepsy
    Laura Mantoan
    Matthew Walker
    [J]. Current Treatment Options in Neurology, 2011, 13 : 355 - 370